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Abstract: In the last two decades, zinc oxide (ZnO) semiconductor Quantum dots (QDs) have been
shown to have fantastic luminescent properties, which together with their low-cost, low-toxicity and
biocompatibility have turned these nanomaterials into one of the main candidates for bio-imaging.
The discovery of other desirable traits such as their ability to produce destructive reactive oxygen
species (ROS), high catalytic efficiency, strong adsorption capability and high isoelectric point,
also make them promising nanomaterials for therapeutic and diagnostic functions. Herein, we review
the recent progress on the use of ZnO based nanoplatforms in drug delivery and theranostic in several
diseases such as bacterial infection and cancer.
Keywords: ZnO nanoparticles; Quantum dots; theranostic; drug delivery; anti-tumour; diabetes
treatment; anti-inflammation; antibacterial; antifungal; wound healing
1. Introduction
For many years, the use of organic dye molecules has allowed us to detect and monitor various
kinds of substances, including drugs, amino acids, nucleotides or materials, both in and outside of cells.
They have also been used to study the process of life chemistry (enzymatic synthesis, immune response,
etc.) or to identify some diseases. However, its use in bio-imaging has been drastically reduced since
the appearance of the quantum dots (QDs) [1]. In general, QDs are more stable to photochemical
degradation, have wide excitation wavelength ranges and narrow and symmetric emission spectra
and can exhibit different colours depending on the size of the particle [2] (the so-called quantum size
effect) [3].
Among the typical QDs, i.e., CdSe, CdTe, CuO, TiO2, etc., ZnO are without any doubt one of the
best choices since they are excellent semiconductors, with luminescent properties [4,5] almost as good
as those of the Cd QDs ones but presenting the advantage of being biodegradable and nontoxic [6].
In fact, although its effect at the nanometre level has not yet been established, ZnO in bulk has already
been considered as safe and approved by the US Food and Drug Administration [7].
ZnO is an n-type semiconductor with an outsized exciton-binding energy (60 meV), a wide band
gap of 3.37 eV at room temperature, a Bohr exciton radius of ~2.34 nm and a high dielectric constant.
Irradiatation of ZnO with UV light favours the promotion of an electron (e−) to the conduction band
and therefore producing a hole (h+) in the valence band, namely the electron/hole pair. Apart from
this typical UV range excitonic emission, the photoluminescence spectrum of ZnO nanocrystals also
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displays a broad visible emission, more suitable for biological imaging. This extended emission
has been ascribed to point defects such as O and Zn vacancies or interstitials and related to surface
oxygen-containing moieties, such as OH groups [8].
Moreover, the luminescence of ZnO nanocrystals can be improved or modulated by doping the
structure with other ions [9,10].
In addition, ZnO QDs also present properties such as the ability to produce ROS, a strong
adsorption capability and an easily tuneable surface that play a crucial role in their use for
biomedical applications.
When ZnO crystals are under UV irradiation in aqueous suspension, these electron/hole pairs
will produce several photochemical reactions generating ROS, making them good candidates for
photodynamic therapy [11]. Usually, when ZnO QDs are excited, the valence band holes present on the
surface, abstract electrons from water and/or hydroxyl ions, giving place to hydroxyl radicals (OH•).
At the same time, the superoxide anion O2- is produced due to the reduction of oxygen [12]. Apart from
the high production of ROS after UV irradiation, ZnO QDs themselves can also generate small amounts
of ROS due to the pro-inflammatory response of the cell against nanoparticles (NPs) [13] and to the
characteristic surface property of ZnO QDs [14,15]. Normally, UV light is required to produce these
electron/hole pairs, however, for ZnO particles whose size is on the nanometre scale, electrons can also
reach the conduction band without the help of UV excitation [16], probably because of the presence of
crystal defects due to their nano-size. Fortunately, this phenomenon is of little importance outside the
cells, where the concentration of ROS is small, but once internalized higher levels of ROS resulting
in cell death. Some studies reveal that ROS production is significantly higher in tumour cells than
in normal ones after being treated with ZnO QDs [17]. It has been reported that various signalling
molecules and ROS are generally more abundant in cells such as tumour cells, due to a rapid metabolic
rate, and high degree of growth and multiplication than in normal cells [18].
ZnO QDs have also be produce a variety of different nano-architectures, including nanospheres,
nanorods, nanotubes, nanorings, nanobelts, nanoflowers, etc. [19–23].
ZnO QDs have a versatile surface chemistry that can easily be modified to prevent aggregation,
improve colloidal stability [24] or to obtain new properties as drug delivery systems (DDS) [25,26].
The use of DDS in nanomedicine has important advantages compared with traditional drugs:
(i) increasing solubility of drugs that cannot be taken up by cells and increasing therefore their
bioavailability [27,28]; (ii) avoiding the degradation of some drugs that are unstable at physiological
or gastrointestinal pH [29,30]; and (iii) reducing the toxicity and side effects of drugs by using target
molecules that increase the selectivity of the treatment [31,32].
Considering their ability to produce ROS, capacity to act as drug delivery systems and their
luminescence properties, we can talk about theranostic nanoplatforms where ZnO QDs not only
perform the role of image agents but also of treatment [33,34].
Herein, in this review, we will summarize the recent progress on the use of ZnO QDs for drug
delivery and theranostic imaging in different pathologies (Figure 1). Approaches to the preparation and
chemical functionalization of ZnO nanostructures for biological applications are very well documented
and this area was a subject of several recent reviews [7,35–39], therefore we are not going to consider
these aspects in this manuscript.
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ROS induction. This situation results in the loss of protein activity balance mediated by zinc as well 
as in an oxidative stress environment that finally produce cell death [41]. 
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Figure 1. Diagram summarizing the main characteristics of ZnO nanostructures (black hexagons) and
their principal applications in biomedicine (red hexagons).
2. ZnO Nanoplatforms for Theranostic in Cancer
In view of the number of publications over the last years, there is no doubt that cancer is the main
objective in terms of the use of ZnO based materials for the treatment of diseases. ZnO QDs slowly
dissolve in physiological pH [40] producing small changes in extracellular zinc concentrations that
cause very little cytotoxicity. However, NPs preferentially internalized in tumour cells as consequence
of the enhanced permeability and retention (EPR) effect. Once inside and because of electrostatic
interactions, ZnO QDs present certain cytotoxicity by themselves based on a higher intracellular release
of dissolved zinc ions due to the acidification of the media, followed by increased ROS induction.
This situation results in the loss of protein activity balance mediated by zinc as well as in an oxidative
stress environment that finally produce cell death [41].
In addition to the synthetic versatility of these materials, we find that ZnO can act as a core, as a
shell around other types of particles or provide an added value to more complex systems. All the
systems are summarized and referenced in Table 1.
Table 1. ZnO nanoplatforms for theranostic in Cancer.
Type of Cell/Animal Used a Type of Device b Responsive Phenomena c Drug/Antibiotic d Reference
MCF-7 ZnO QDs - Adsorbed DOX [42]
MCF-7R, MCF-7S ZnO QDs pH Loaded DOX [43]
MDA-MB-231, HeLa, NCI/ADR-RES,
MES-SA/Dx5 ZnO QDs pH Adsorbed DOX [44]
- ZnO QDs , ultrasounds Loaded DOX [45]
HeLa g ZnO QDs pH Adsorbed DOX [46]
MCF-7, MDA-MB-231, nude mice F ollow ZnO NPs pH Loaded paclitaxel [47]
MDA-MB-231, HBL-100, mice FA ZnO Nanosheets pH, heat Loaded DOX [48]
SMMC-7721 ZnO nanorod UV radiation - [12]
HeLa, PC3 L t anide–ZnO QDs UV, X-ray, γ-ray radiation - [33]
SMMC-7721 ZnO nanorod UV radiation DOX complex [49]
HNSCC ZnO QDs UVA irradiation Paclitaxel, cisplatin [50]
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Table 1. Cont.
Type of Cell/Animal Used a Type of Device b Responsive Phenomena c Drug/Antibiotic d Reference
MCF-7 MUC1 aptamer S2.2. ZnO QDs UV radiation Loaded DOX [51]
BxPC-3, tumour-bearing nude mice Gd-Polymer–ZnO QDs pH Adsorbed DOX [34]
HEK 293T, HeLa FA-SiO2 ZnO NPs pH Loaded DOX [52]
HeLa Lipid ZnO NCs pH - [53]
Caco-2 TiO2@ZnO–GO and TiO2@ZnO pH Loaded Cur [26]
- Fe3O4@ZnO@mGd2O3:Eu@P(NIPAm-co-MAA)
Microwave, Magnetic
radiation VP-16 [54]
MCF-7 β-CD-Fe3O4@ZnO: Er3+, Yb3+
Microwave, Magnetic
radiation VP-16 [55]
HeLa ZnO MSNs pH Loaded DOX [56]
BxPC-3 Mg ZnO MSNs pH Loaded CPT,adsorbed Cur [57]
HeLa, mouse UCNPs@mSiO2-ZnO pH Loaded DOX [58]
- ZnO-pSiO2-GSSG NPs Protease, redox, pH Loaded amoxicillin [59]
HepG2 L-pSiO2/Cys/ZnO NPs Redox, pH Loaded DOX [25]
A549 ZnO-MCNs pH Loaded MIT [60]
HeLa ZnO@-Dextran microgels pH Loaded DOX [61]
a MCF-7: Human breast cancer cell; MCF-7S/MCF-7R: Human breast cancer cell sensitive/resistant to doxorubicin;
MDA-MB-231: epithelial, human breast cancer cell; HeLa: Human epithelial cells from a fatal cervical carcinoma;
NCI/ADR-RES: Ovarian tumour cell; MES-SA/Dx5: Multidrug-resistant human sarcoma cell; HBL-100: Human,
Caucasian, breast cancer cell; SMMC-7721: Human hepatocarcinoma cell; PC3: Human prostate cancer cell;
HNSCC: Head and neck squamous cell carcinoma; BxPC-3: Human pancreatic cancer cell; HEK 293T: Human
embryonic kidney cells; Caco-2: Human epithelial colorectal adenocarcinoma cell; HepG2: Human liver cancer
cell; A549: Adenocarcinomic human alveolar basal epithelial cell. b ZnO QDs: Zinc oxide quantum dots;
FA: Folic acid; QDs: Quantum dots; MUC1: membrane glycoprotein which is highly expressed in most
breast cancers; Aptamer S2.2.: (5′-COOH-GCA-GTT-GAT-CCT-TTG-GAT-ACC-CTGGTTTTT-FAM-3′) SiO2: Silica;
NCs: Nanocrystals; MABG: TiO2@ZnO–GO: ZnO coated mesoporous titanium oxide QDs containing graphene
oxide; Fe3O4@ZnO@mGd2O3:Eu@P(NIPAm-co-MAA): iron oxide QDs coated with ZnO and mesoporous
Gd2O3:Eu shells with a polymer poly[(N-isopropylacrylamide)-co-(methacrylic acid)] (P(NIPAm-co-MAA)) to
gate the mesoporous; K8(RGD)2 cationic peptide containing 2 RGD sequences; β-CD-Fe3O4@ZnO: Er3+,
Yb3+: β-cyclodextrins functionalized iron oxide QDs doped with Er3+ and Yb3+ coated with ZnO; ZnO MSNs:
Mesoporous silica nanoparticles with ZnO QDs as cap of the pores; UCNPs@mSiO2-ZnO: Lanthanide-doped
upconverting nanoparticles with a mesoporous silica layer and ZnO QDs as gatekeeper; ZnO-pSiO2-GSSG NPs:
ZnO QDs as cups of oxidized glutathione (GSSG) amino-functionalized silica NPs; L-pSiO2/Cys/ZnO NPs:
Lemon like silica NPs with cysteine and ZnO QDs cups; MCNs: Mesoporous carbon nanoparticles. c UV: Ultra
violet. d DOX: Doxorrubicin; Cur: Curcumin; VP-16: Chemotherapeutic drug etoposide; CPT: Camptothecin;
and MIT: Mitoxantrone.
2.1. ZnO Core Nanosystems
Regarding systems that use ZnO as core for the treatment of cancer, in 2016, Vaidya et al. adsorbed
doxorrubicin (DOX) onto the surface of ZnO QDs (ZD QDs) and studied their anticancer activity in
MCF-7 cells compared to that presented by free DOX, ZnO QDs, and a mixture of the latter two. It was
observed that the combined addition of ZnO QDs and DOX presented higher antitumour capacity
than any of its components separately but lower than the effect of ZD QDs, maybe because of a better
targeting and a higher retention of the DOX loaded QDs in the tumour cells [42]. At the same time,
Liang et al. performed a similar study with MCF-7R and MCF-7S cells. In this case, they explained
the release of the drug due to the degradation of ZnO in response to pH after internalization of the
QDs into the endo/lysosomes. They also performed a real-time tracking of the drug release. Although
the two components separately exhibited fluorescence, their intensity was quenched after ZD QDs
formation. However, after the degradation of ZnO and the consequent release of the DOX, the intensity
of the fluorescence increased again [43]. In 2017, Zhu et al. went one step further and proposed ZnO
QDs as a multifunctional platform for cancer treatment (Figure 2a). They studied the synergistic
anticancer activity due to the ROS generation of ZnO QDs and DOX in several cell lines but also
studied their effect in macrophages or in tumour (stem-like) cells. In stem cells, it was observed that
ZnO QDs affected the expression of CD44, leading to a marked decrease in migration, accumulation
of mutations and cell adhesion, but increasing sensitivity to antitumour treatment. In macrophages,
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a polarization towards the phenotype M1 was observed, increasing the antitumour effectiveness and
immune response of DOX [44].Nanomaterials 2018, 8, x FOR PEER REVIEW  5 of 27 
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et al. synthesized ZnO QDs with a polymeric shell, coordinated with Gd3+ ions and adsorbed DOX to 
create a versatile ZnO-Gd-DOX nanodevice. It was a bifunctional probe for both in vitro fluorescent 
and in vivo animal imaging, due to the strong red emission of ZnO-Gd-DOX in the range of 600–800 
nm and magnetic resonance imaging (MRI) contrast due to Gd3+ ions, which were immobilized onto 
the ZnO surface through proper coordination with carboxyl groups of the polymer. This rendered an 
outstanding relaxivity for MRI. Most importantly, these nanomaterials also demonstrated a very 
promising antitumour activity. BxPC-3 tumour-bearing nude mice were injected with different 
agents to study chemotherapy efficacy. As shown in Figure 3a, the tumour in the control continued 
growing, while those treated with DOX, Doxil or ZnO-Gd-DOX QDs remained more or less the same. 
H&E (hematoxylin and eosin) staining of tumour slices (Figure 3b) showed that the cells in the control 
retained their normal membrane and nuclear structures, and the cells treated with DOX or Doxil were 
damaged partly, while almost all cells were severely destroyed after ZnO-Gd-DOX treatment. This 
Figure 2. (a) Scheme of the multiple proposed effects of ZnO QDs as a multi-functional antitumour
treatment. Reproduced with permission from [44]. American Chemical Society, 2017; (b) Scheme of the
combined mechanism of action of DOX-FA-ZnO NS for breast carcinoma therapy. Reproduced with
permission from [48]. Elsevier, 2017.
Bahadur et al. demonstrated that the application of ultrasound irradiation in ZD QDs can be used
for on-demand pulsatile release of DOX molecules [45]. To increase the selectivity and luminescence of
the nanocarrier, Zhu et al. designed Mg ZnD QDs functionalized with Folic Acid (FA) and studied
their toxicity in HeLa cells [46]. Pathak et al. also used FA as targeting agent to synthesize a new ZnO
hollow-nanocarrier containing paclitaxel as model drug. Initially, they suspended carbon spheres in
zinc acetate solution and added ammonia to form a zinc hydroxide layer onto the surface of the carbon
spheres. After that, the carbon was removed by pyrolysis, giving rise to the hollow ZnO spheres. Then,
the NPs were loaded with paclitaxel and functionalized with FA. The effectiveness of the nanosystem
was successful both in vitr by producing cytotoxicity with breast cancer cells and in vivo by reducing
MDA-MB-231 xenogr ft tumours in nud mice [47]. FA mo ified zinc xide nanosheets (Ns) were also
propos d by K nn et al. as a chemo-photothermal dev ce for breast cancer therapy. The xp iments
showed that the combination of both therapies (chemotherapy and ph tothermal therapy) resulted
in higher percentages of cell death than either of them separately. In addition, in vitro and in vivo
experiments showed no adverse effect or toxicity on blood stream. In Figure 2b, a scheme of the
combined mechanism of action of these nanosheets is presented [48]. As explained in the Introduction,
the irradiation of ZnO QDs with UV light increases the production of ROS, enhancing the antitumour
capacity of the QDs. Several groups have studied this effect in tumour cells with pure particles [12],
particles doped with other ions [33], in combination with different antitumour agents [49,50] or using
an aptamer as targeting agent [51].
2.2. ZnO Core Nanocomposites
Several nanocomposites based on ZnO QDs in combi ation with ot er materials to obtain
new na ocomposites with syn rgist theranostic effects have also been reported. For example,
H. Möhwald et al. synthesized ZnO QDs with a polymeric shell, coordinated with Gd3+ i s and
adsorbed DOX to create a versatile ZnO-Gd-DOX nanodevice. It was a bifunctional probe for both
in vitro fluorescent and in vivo animal imaging, due to the strong red emission of ZnO-Gd-DOX
in the range of 600–800 nm and magnetic resonance imaging (MRI) contrast due to Gd3+ ions,
which were immobilized onto the ZnO surface through proper coordination with carboxyl groups of
the polymer. This rendered an outstanding relaxivity for MRI. Most importantly, these nanomaterials
also demonstrated a very promising antitumour activity. BxPC-3 tumour-bearing nude mice were
injected with different agents to study chemotherapy efficacy. As shown in Figure 3a, the tumour in
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the control continued growing, while those treated with DOX, Doxil or ZnO-Gd-DOX QDs remained
more or less the same. H&E (hematoxylin and eosin) staining of tumour slices (Figure 3b) showed
that the cells in the control retained their normal membrane and nuclear structures, and the cells
treated with DOX or Doxil were damaged partly, while almost all cells were severely destroyed after
ZnO-Gd-DOX treatment. This result confirmed that ZnO-Gd-DOX QDs performed better than the
other agents. Finally, they also observed that ZnO-Gd-DOX QDs had no detectable toxic side effects to
mice, and the whole QDs could be biodegraded and excreted from the mice body [34].
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Qu et al. combined the advantages of mesoporous silica nanoreactors, DOX, FA, and ZnO QDs to
develop a drug carrier effectively protected from non-specific degradation (ZnO-DOX@F-mSiO2-FA).
They demonstrated that the mesoporous silica shell protected the ZnO-DOX device from non-specific
protein degradation, while retained its sensitivity to pH-responsiveness. To perform the experiments,
HeLa and HEK 293T cells, which are, respectively, positive and negative for folate receptor,
were elected as mod l cells. After th reatment with ZnO-DOX@mSiO2-FA, a clear increase in
positive annexin V-FITC HeLa cells was observed when comp red with control ones. The results
also showed an effective targeting due to the presence of the folic acid as ZnO-DOX@mSiO2-FA
presented selective toxic capacity toward HeLa cells [52]. Cauda et al. designed new lipid-coated
ZnO nanocrystals (NCs) to achieve a better stability in biological samples. Their results showed that
lipid-coated ZnO NCs presented stable colloidal dispersions in cell culture medium and simulated
human plasma for 25 days. However, after being suspended, the pristine and amine-functionalized
NCs quickly aggregated, remaining stable for less than an hour. Even though internalization of
lipid-shielded ZnO NCs in HeLa cells was higher compared to the other samples, its toxicity was
lower, showing a lower toxicity/particle ratio [53].
2.3. ZnO Coated Nanodevices
Due to its high bioc mpatibility, in recent years ZnO has been used as a c ati g for other
types of QDs that present more toxicity. In comparison with the pegylation that also provides
stability and biocompatibility, the use of ZnO as a coating provides added values such as luminescent
properties or ROS production, among others, that cannot be achieved by PEG functionalization.
For instance, H. Danafar et al. recently reported a new system, TiO2@ZnO NPs, where ZnO is used
to coat mesoporous TiO2 QDs. They loaded the mesopores with curcumin (Cur) and studied their
pH-dependent in vitro anticancer effect against human epithelial colorectal adenocarcinoma cells.
The cy ot xic capacity was also compared with a similar system that contained graphene oxide
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(GO), (which has probe to be quite efficient in the treatment of cancer of colon) [62,63] as final layer,
TiO2@ZnO–GO. Opposite to what was expected, the presence of GO did not increase toxicity. Proof of
this is that TiO2@ZnO showed higher killing capability against Caco-2 cancer cell than the ones that
contained GO. Therefore, there was reduced toxicity of ZnO nanoparticles [26]. Authors suggested that
effect could be because of the presence of ZnO nanoprecipitation on the tumour cells [64,65]. In 2015,
Wang et al. reported two different systems based on iron oxide QDs coated with ZnO and sensitive to
magnetic and microwave radiations. In both cases, the Fe3O4 core functioned for magnetic targeting,
allowing them, with the help of an external magnet, to concentrate the NPs in the desire tissue,
while the ZnO shell acted as a microwave absorber that facilitated the release of the drug due to an
increase in temperature. The first system consisted of Fe3O4@ZnO@mGd2O3:Eu@P(NIPAm-co-MAA)
NPs used as drug carrier of the cytotoxic etoposide (VP-16). The mesoporous Gd2O3:Eu shells
acted as drug nanocarrier, being the poly[(N-isopropylacrylamide)-co-(methacrylic acid)] polymer
(P(NIPAm-co-MAA)) the temperature sensitive caps that responded to microwave application.
The experiments demonstrated that the ZnO shells effectively absorbed and converted microwave
irradiation to heat; as a result, P(NIPAm-co-MAA) contracts, unblocking the mesopores and triggering
the release of about 81.7% of the entrapped VP16 drug within 10 h [54]. The second nanoprobes
were core–shell structured β-CD-Fe3O4@ZnO:Er3+,Yb3+ nanoparticles and their scheme of synthesis
is shown in Figure 4a. In this system, the drug was stored in the inert cavity of the β-cyclodextrins
(β-CD) due to hydrophobic interactions. The ZnO shell doped with Er3+ and Yb3+ not only acted as
microwave absorber that produd a thermal response (similar to the previous one) but also provided
fluorescence imaging for in vitro detection. The data showed that β-CD-Fe3O4@ZnO:Er3+,Yb3+ NPs
were able to transform the microwaves into localized internal heating, allowing the release of the
drug in a control manner by selecting the microwave exposure time and the number of cycles applied
(Figure 4b). The MTT assay showed that the NPs had a strong targeting effect producing high rates of
tumour cell death almost without affecting healthy ones [55].
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2.4. ZnO QDs as Po Caps
ZnO QDs are sensitive to pH and can be synthesized at different sizes. These two features make
them great candidates to act as “gatekeeper” of the pores of bigger systems, allowing to enclose in
its interior different drugs that will only be released under acidic tumour conditions after dissolution
of the QDs. Based on this idea, the mesoporous silica nanoparticles with a large load capacity and a
pore diameter around 2.5 n s em to be the perfect combinati n [66–68]. In fact, several groups have
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proposed different systems based on the combination of these two components, mesoporous silica
nanoparticles as storage material and ZnO QDs as cap of the pores. It was in 2011 when G. Zhu et al.
reported this combination for the first time. They synthesized MSN with amino groups inside the pores
and carboxylic acid groups outside and loaded them with DOX. Finally, they used amino functionalized
ZnO nanolids (Nls) to close the pores through amide coupling with 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC). The stimulus-responsive capacity of the DOX-loaded ZnO MSNs were studied
at different pH values. At physiological pH (7.4), negligible DOX release was observed; however,
at pH 5.0m a fast DOX release was observed due to the dissolution of the ZnO Nls (Figure 5a). As can
be seen in Figure 5b, the viability studies demonstrated that ZnO MSNs@DOX led to high death rates
in HeLa cells at very low concentrations (6.25 µg/mL) [56].
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Two years later, the same group presented a new system whose novelty lay in the fact that ZnO
QDs were also used as chelate forming agents of a second hydrophobic drug (curcumin) that was
significantly loaded onto the surface of the ZnO Nls. Cell viability experiments confirmed that the
combi ation of both drugs presented a high cytotoxic effect even for small device concentrations such
as ~3 µg/mL [57]. In 2015, H. Zhang et al. came out with a mul ifunctional nanotheranostic agent with
lanthanide-doped upconv rting nanoparticl s (UCNPs) (NaYF4: 20%Yb3+, 2%Er3+/NaGdF4: 2%Yb3+)
as the core for the UCL/CT/MRI trimodality imaging. In this system, called UCNPs@mSiO2-ZnO,
the core was cover with a mesoporous silica layer, loaded with a drug and finally pH-sensitive
ZnO QDs were used to cap the pores. UCNPs@mSiO2-ZnO demonstrated great abilities to be
employed as contrast agents for tri-modal imaging, both in vitro and in vivo. The cytotoxic effect of
the loaded NPs was studied against HeLa cell and the results showed higher therapeutic effectiveness
than that obtained with the free DOX [58]. Lei Sun et al. prepared a new protease/redox/pH
triple-sensitive delivery nanodevice through the combination of fluorescent ZnO QDs, oxidized
glutathi ne (GSSG) and ami o-functionalized pSiO2 NPs. In that case, GSSG was linked to the
surf ce of NH2-functionalized pSiO2 NPs through amido onds. T en, ZnO QDs were also covalently
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attached to GSSG acting as fluorescence probes and caps of the pores. In that system, the release of
the amoxicillin cargo was susceptible to being triggered by three different stimuli: (i) the degradation
of ZnO QDs in acid media characteristic of tumour environments; (ii) the break of the GSSG linkers
through amido bonds by proteases; or (iii) the break of the GSSG linkers through disulphide bonds by
the presence of reduced glutathione (GSH). Three different release experiments were performed to
study the effect of each of the stimuli separately. It was observed that the amoxicillin release was slower
because of GSH than that in the acidic pH conditions, which authors attribute to the presence ZnO
QDs hindering GSH from entering the mesoporous structure to break the disulphide bonds. However,
this dependency showed that the addition of protease K was higher, achieving around 66% of cargo
release in only 6 h. The authors expected that this triple-stimuli responsive nanodevice had great
applications for antitumour therapy [59]. One year after, in 2017 the same research group enhanced
the GSH response of the nanodevice by anchoring the ZnO QDs through cystine (Cys) molecules
and studied the in vitro cytotoxic effect of the system against HepG2 cells. After incubation for 48 h
without drug cargo, the cell viability was about 96.6%, even at a high concentration of 500 µg/mL,
which demonstrates that both L-pSiO2/Cys and L-pSiO2/Cys/ZnO presented good biocompatibility.
However, when the same experiment was carried out, the DOX-loaded L-pSiO2/Cys nanoparticles
displayed a concentration-dependent cytotoxicity significantly higher than that observed for free
DOX [25]. Mesoporous carbon nanoparticles (MCNs) present similar characteristics to those described
for MSNs in terms of mechanical and structural properties. That is why X. Du et al. reported a
new carboxylated MCNs were ZnO QDs were covalently linked via dual amide bonds to minimize
premature release of mitoxantrone (MIT) drug. The toxicity of the system itself was studied in vitro
in A549 cells showing low toxicity after 48 h of incubation. However, when ZnO-gated MCNs were
loaded with MIT the tumour killing capability was clearly increased to values of about 65% even
at small drug concentrations such us 0.066 ng/cell. As can be seen in Figure 5c, the release of the
drug was monitored by confocal microscopy, showing that MIT was exclusively released inside the
cells without premature release in the extracellular media. This proved that the release is due to the
dissolution of the ZnO QDs by a decrease in the pH inside the cell [60].
2.5. ZnO QDs That Provides an Added Value to Other Systems
Microgels are three-dimensional networks which have various applications due to their facile
fabrication, their drug loading capacity and the possibility to functionalize them to obtain stimuli
responsive effect. There are two strategies to achieve these stimuli responsive microgels: utilizing
sensitive polymers and designing microgels with degradable crosslinkage. The latter strategy was
used by J. Feng et al. to design ZnO@Dextran microgels loaded with DOX, were amino-modified ZnO
QDs acted as pH-sensitive crosslinkers to carboxymethyl dextran (CMD)(Figure 6a–c). Since ZnO
QDs are dissolvable at pH lower than 5.5, degradation of the ZnO@Dextran microgels at different
pH values (7.4, 5.0, and 3.0) was investigated. As shown in Figure 6d, the digital photos were taken
after vortexing of the microgels in different buffers for several minutes. It was observed that the
hybrid microgels dissolved completely at pH 5.0 and 3.0, yielding a clear solution but in the case
of pH 7.4 a non-transparent solution could be seen, indicating that most of the microgel particles
remained intact. To evaluate tumour therapeutic effect of the DOX-loaded ZnO@Dextran microgels,
the cytotoxicities of ZnO@Dextran/DOX and the two control materials (ZnO@Dextran microgels and
free DOX) were investigated by the authors in Hela cells by MTT assays. By an unusual procedure,
the cells were incubated with one of those materials under pH condition of 5.0 and 7.4 for 24 h,
respectively. As shown in Figure 6e, ZnO@Dextran/DOX showed more pronounced cytotoxic effects
on Hela cells at pH 5.0 than 7.4 [61].
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3. ZnO Nanoplatforms for Bacterial Infection
The increase in the quality of life as been associated with an increase in the longevity of
the population and, therefore, to the number of fragile and immunocompromised people, who are
candidates to suffer a bacterial infection. In addition, despite aseptic surgical techniques, the number of
surgical interventions that are practiced each year is increasing, making it the appearance of a bacterial
infection associated with implants even more possible.Thus, bacterial infections have attracted great
attention from both the medical community and public worldwide [69]. There are several obstacles
that hinder the effectiveness of bacterial infection treatments: (i) the lack of early stage detection
methods [70], which n clinic are currently limited to indi ect im ging odalities; (ii) the overuse
of antibiotics favouring the appearance of bacter a resistant to mul ipl drugs, leading to antibiotic
ineffectiveness [71]; (iii) biofilm formation, which has an extracellular matrix that makes it resistant to
antibiotics [72]; amd (iv) intracellular infections, whose difficulty lies in the wide variety of mechanisms
used by bacteria to ensure their survival such as inhibition of the phago/lysosome fusion, resistance to
lysosomal enzymes attack, etc. [73].
Thus, it would be necessary to develop clinical imaging tools able to selectively attack invasive
bacteria and/or biofilm, allowing early detection [74] and that at the same time can release some
antibiotics or produce so e therapeutic effect in the infected area [73]. Luminescent ZnO QDs,
with high surface-to-volume ratio, c pacity of ROS pr ductio d a strong surface chemistry,
meet all he necessary r quiremen s to adequat ly treat bacterial infection [75]. Besides, recen studies
evidence that NPs can present antibacterial capacity without having any side effect on human cells,
that is, showing selective toxicity [76]. This selectivity might be because of differences in the action
mechanisms in bacteria and mammal cells. For bacteria, the most recognized NPs action mechanisms
so far are ROS and free radical generation, bacterial cells adhesion and penetration, biofilm penetration
and changes on bacteria metabolic activity and gene expression [77].
It has become clear that biofilm-grown cells exhibit different properties than planktonic bacteria,
therefore nanodevices with different properties need to be use for the treatment of each one [78].
3.1. ZnO Nanoplatforms for Planktonic Bacteria Treatment
Z O QDs have proven their effectiveness against a bro d sp ctrum of pat ogenic microorganisms,
even though the response they produce in Gram-positive/-negative studies are different, probably due
to differences in the membrane composition and in the intracellular antioxidant content of both types
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of bacteria [7]. It has also been reported that the antimicrobial capacity of the ZnO clearly depends on
the size of the QDs, i.e., with smaller sizes being more effective [79].
The antibacterial effect of ZnO QDs on Campylobacter jejuni was investigated by X. Shi et al. for
inhibition and inactivation of cell growth. In this study, the effect of ZnO QDs on the integrity of
the bacterial membrane and on the expression of different bacteria genes was studied. Ethidium
monoazide (EMA) is a fluorescent label able to bind DNA and inhibit PCR amplification. However,
the bacterial membrane is impermeable to EMA so the union only take place if the membrane has been
damaged. EMA-PCR experiments were carried out and a clear reduction on DNA amplification was
observed for the samples treated with ZnO QDs. Besides an increase expression of ahpC and katA,
two common genes that express oxidative stress, was also observed. These PCR results suggested that
the antibacterial mechanism of ZnO nanoparticles in Campylobacter was most likely due to disruption
of the cell membrane and oxidative stress [80]. I. Ahmad et al. performed a comparative experiment
to study the antibacterial activity of ZnO QDs against different types of bacteria, including some
Gram-negative (Vibrio cholera, Campylobacter jejuni and Escherichia) and Gram-positive (methicillin
resistant Staphylococcus aureus) studies. After 4 h of ZnO QDs exposure, a clear decrease in bacterial
viability was observed in all cases, being especially effective against C. jejuni where bacterial death
amounted to 65%. On the other hand, V. cholerae were the least affected bacteria seeing its population
reduced by only 27% [75]. S. Arastoo et al. synthesized Ag and ZnO QDs and mixed them to study their
antibacterial effect against Mycobacterium Tuberculosis (Mtb) growth inside macrophages. The toxicity
of the QDs in THP-1 leukemic cells was also studied. Results showed that the 8ZnO/2Ag ratio was the
most effective since it had high antibacterial capacity against Mtb both in vivo and in vitro but without
affecting the cellular viability of THP-1 cells [81]. In 2016, R. Jalal et al. used different techniques
(fluorescence and scanning electron microscopy, flow cytometry and DNA extraction) to elucidate
the mechanism of action of ZnO QDs administered alone and in combination with two antibiotics
ciprofloxacin and ceftazidime. The authors demonstrated that sub-inhibitory concentrations of ZnO
QDs were enough to significantly increase the uptake and antibacterial capacity of both antibiotics.
The effect of light on increasing ROS production for the treatment of bacteria had also been
studied. J. Gupta and D. Bahadur reported the antibacterial and anticancer activity effect of visible
light irradiation on Cu substituted ZnO nanoassemblies (Cu-ZnO NAs). First, different concentrations
of Cu were studied to optimize the ROS production with Cu5-ZnO being the most efficient material.
The data showed that the NAs themselves had antibacterial activity. Although irradiation with visible
light alone had a negligible effect on cell viability, the combination of light with the Cu5-ZnO NAs
produced 100% of bacterial death after 30 min of light application [82].
Opposite to what has been said so far, VanEpps et al. have recently published an article that
casts serious doubts on ROS production being responsible for the antibacterial efficacy of ZnO QDs.
They based their conclusions on experiments made with two different types of ZnO nanoparticles
against S. aureus bacteria. Bacteria were exposed to both types of NPs and concentrations of H2O2 that
presented an equivalent amount of bacterial killing capacity. Additionality, the same experiment was
carried out but in presence of the antioxidant N-acetylcysteine (NAC). Results showed a clear recovery
of those bacterial colonies treated with H2O2 but no changes in the ones treated with ZnO laying bare
that the decrease in bacteria population was not due to ROS production (Figure 7).
Studies on the effect of ZnO NPs on gene expression were consistent with that as oxidative
stress genes were down regulated. In addition, the effect on anaerobic carbohydrate metabolism and
energetics with upregulation of the UMP biosynthesis pathway was also proposed as the reason for
ZnO NPs antibacterial activity [83].
As in the case of cancer, the use of ZnO nanosystems for the treatment of bacterial infections is
not only limited to QDs themselves, but ZnO QDs can also be used as a component of more complex
systems. In 2015, Parkin et al. incorporated crystal violet and zinc oxide nanoparticles (CVZnO)
into medical grade polyurethane polymers to synthesize new surfaces with antibacterial activity.
The antibacterial capacity of these surfaces after light irradiation proved to be lethal for the two types
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of bacteria studied: E. coli and S. aureus, for Gram-negative and Gram-positive, respectively [84].
One year later, Gu et al. developed a fluorescent nano-probe MPA@ZnO-PEP by the combination of
silica stabilized ZnO QDs (ZnO@SiO2) with PEP, a peptide fragment for bacteria targeting, and MPA,
a near infrared dye. This fluorescent nanodevice proved to be a potent tool to bacteria detection both
in vitro and in vivo since it allowed to differentiate between sterile inflammation and bacterial infection.
To increase the antibacterial capacity, vancomycin (Van) was also incorporated to the nanoplatform to
form the so-called MPA/Van@ZnO-PEP. Antibacterial (S. aureus and B. subtilis) test were performed,
showing that for B. subtilis a concentration of 1mg was enough to produce bacterial inhibition, needing
2 mg to achieve the same effect in S. aureus. In both cases, it was a much lower concentration than
that required for free Van. Furthermore, authors wanted to test the efficacy of the nanosystem against
antibiotic resistant bacteria. Therefore, Van was substituted by methicillin (Met) and the antibacterial
capability of MPA/Met@ZnO-PEP was studied against to a S. aureus strain which was resistant to this
antibiotic (MRSA). While bacteria incubated with free Met or the unloaded nanoplatform exhibited a
viability comparable to the control, those incubated with MPA/Met@ZnO-PEP reduced their viability
to a 60% for a concentration of 64 µg/mL of NPs [85].
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3.2. ZnO Nanoplatforms for Biofilm Treatment
Bi films are defined as complex com unities f mi roorganisms that grow emb dded in a
self-produced protective extracellular matrix made of polysaccharides, DNA and proteins. The main
problem related with biofilm formation is that at this point bacteria becomes antibiotic resistant
and more tolerant to disinfectant chemicals or to the response of the immune system, increasing
the probability to degenerate into chronic infections [72]. Clinical observations and experimental
studies clearly indicate that a treatment exclusively based in the administration of antibiotics is
usually insufficient to eliminate the biofilm. Hence, to effectively eradicate biofilm infections, new,
more complex trategies such s the use of ZnO nanodevices are need d.
Jurše˙ as et al. focused their research on the eff ct of unmodified ZnO nanorods (NRs) against
strongly resista t bio-films after 405 nm light excitation. T refore, different bacteria biofilms were
grown onto surfaces covered by ZnO NRs. Then some of them were exposed to light while the others
remained in darkness. The results showed that neither the NRs nor the irradiation with light presented
by themselves any type of toxicity against planktonic bacteria or biofilms (see Figure 8).
However, for those samples coated with ZnO NRs and subject to light, the biofilm was
substantially reduced. Besides, it was observed that inactivation of biofilm growth was strongly
dependent on light dose. Moreover, different degrees of effectiveness were observed for the same
treatment depending on the type of bacteria used, with L. monocytogenes biofilms being the most
susceptible population and E. faecalis the most resistance one [86].
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Figure 8. Fluorescence micrographs of E. coli biofilms gro n up onto ZnO NRs surfaces: (a) without;
or (b) with lig t treatment. Alive cells were staine i and dead cells in red; (c) Light-dose
depen nce cytotoxic effect on E. faecalis MSCL 302, L. monocytogenes ATCL3C 7644 and E. coli O157:H7
biofilms grown up onto ZnO NRs coated surfaces. Non-illuminated biofilms grown on plastic surfaces
were used as control and effect the NRs in absence of light was expressed as dark toxicity. Reproduced
with permission from [86].
3.3. ZnO Nanoplatforms for Planktonic and Biofilm Treatment
The ultimate treatment would be one that involve a simultaneous attack of the planktonic bacteria
and the undesired bacterial biofilm. Recently, s veral systems based on ZnO QDs have een shown to
fulfil this ouble functionality. An example of this was the research carrie out by A.A. Al-Khedhairy
et al. about the effect of ZnO QDs against bacterial strai Pseudomonas. For the study of the effect
on bacteria, several plates were cultured with increasing QD concentrations, observing a maximum
inhibition at 100 mg/mL of ZnO QDs. To follow the inhibition of biofilm formation, crystal violet
dye was employed as stain. The results showed a significant inhibition of the biofilm formation at
50 and 100 mg/mL of ZnO QDs [87]. J. Lee et al. also used Pseudomonas aeruginosa as bacteria but
in this case the effect of thirty-six metal ions was studied. Among all of them, zinc ions and ZnO
QDs were able to efficiently reduce P. aeruginosa biofilm as well as the production of different bacterial
growth signals [88]. Similarly, A. Jamalli et al. studi the effect of ZnO QDs in the bi film formation
and the antigen 43 expression (an important surface protein in E. coli whi h is encoded by flu gene).
The authors observed that ZnO QDs produced inhibitory effects on biofilm formation in uropathogenic
Escherichia coli (UPEC) isolates. Results also showed that concentrations of QDs lower than the amount
needed to inhibit biofilm formation were nevertheless enough to significantly decrease the expression
of the flu gene in UPEC [89].
Chakrabarti et al. studied the effect of ZnO QDs on two biotypes of cholera bacteria (classical
and El Tor) observing greater efficiency for El Tor strain both in biofilm and in planktonic forms.
The authors were not completely sure about the reason for the differences in susceptibility. However,
according to their suggestion, it might be due to some differences in membran structure or gene
expression betwe the two biotypes. Results showed that ZnO QDs produced ROS that damaged
bacterial membrane and substantially modified their morphology. Authors also tested the antibacterial
capacity of the QDs in cholera toxin (CT) mouse models. As can be seen in Figure 9a, controls presented
strong fluid accumulation in the loops and therefore a big organ distention and diarrheal symptoms.
Fluid accumulation values equal to 0.2 or higher are considered a positive result in diarrhoea.
Figure 9b shows that a single administration of ZnO QDs with CT was enough to considerably reduce
intestinal fluid accumulation. The synergist effect of the combine administration of ZnO QDs and
kanamycin was also studied achieving a considerably increased killing capability of 85–87% killing
comp red with 50–70% of the QDs alone [90].
Another important contribution f ZnO against inf ction is its us as coating on implant materials.
In 2016, Rose et al. reported the effect of three different ZnO QDs structures (spheres, plates and
pyramids) in planktonic growth and biofilm formation after surface coating. Several bacterial types
were used, and planktonic growth experiments revealed that S. epidermidis and S. aureus (Gram-positive
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bacteria) presented dose dependent reduction for all ZnO structures. However, K. pneumonia and E. coli
(Gram-negative bacteria) were not affected by the presence of ZnO QDs up to 667 µg/mL, probably
because of differences in bacterial surface hydrophobicity.
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Biofilm formation experiments on polystyrene ZnO QDs coated surfaces demonstrated no
significant differences related with the particle morphology. Nevertheless, notable differences were
observed in terms of the type of bacteria studied allowing a reduction in biofilm formation only for
Gram-positive bacteria [91]. De Fátima Montemor et al. studied the antibacterial and antibiofilm effect
of nano-and micro-sized ZnO coatings against MRSA. Which found that only the nano-sized coating
was able to reduce biofilm formation. Additionally, the combination effect of ZnO coating followed by
the a ditio of diff rent a tibiotics in sub-inhibitory concentrations was also analysed. The results
showed a greater antibacteri l efficacy due to the combine treatment with gentamicin, no differences
when adding trimethoprim and even an infection worsening in the presence of rifampicin, ciprofloxacin,
and vancomycin [92]. Recently, Wang et al. reported a new method to coat implant surfaces based
on the combination of two different ZnO structures named as ZnO nanorods−nanoslices hierarchical
structure (NHS). Authors modified the surface of two commonly used implant materials (titanium
and tantalum) with NHS and each of the structures separately and studied their antibacterial capacity
against E. coli and S. aureus under different times. Results proved that ZnO nanoslices rapidly released
(48 h) allowing to kill bacteria in early stages. On the other hand, ZnO nanorods that presented higher
stability needed around two weeks to present a bacteria killing capability. ZnO NHS, which combined
both elements presented a two-stage antibacterial effect. The antibacterial efficacy of ZnO NHS was
also studied by mice test in vivo, showing not only good results onto the implant surfaces but in the
surrounding areas where an effective sterilization was also observed [93].
However, despite the numerous advantages of the antibacterial character of ZnO QDs, a poor
control of their residues can have negative effects on soil-dwelling microorganisms responsible for
numerous activities of great impact on the soil quality such as plant protection, biodegradation,
ecological balance and nutrient recycling [94].
All recent advances made for the tre tment of bacterial inf ction with ZnO nanoplatforms are
summarized in Table 2.
Nanomaterials 2018, 8, 268 15 of 27
Table 2. ZnO nanoplatforms for theranostic bacterial infection.
Type of Bacteria Used a Type of Device b
Responsive
Phenomena c Drug/Antibiotic
d Reference
C. jejuni ZnO QDs - - [80]
EPEC, C. jejuni, V. Cholerae, MRSA ZnO QDs - - [75]
THP-1, M. tuberculosis ZnO QDs + Ag QDs - - [81]
A. baumannii ZnO QDs - Coadministered Cip, Cef [95]
E. coli Cu-ZnO NAs Visible light - [82]
MRSA ZnO-NPYs, ZnO QDs - - [83]
S. aureus, E. coli CVZnOpolyurethane surface White light Loaded CV [84]
S. aureus, B. subtilis, MRSA, S.
aureus or B. subtilis infected mouse MPA@ZnO-PEP - Loaded Met, Van [85]
MSCL 302, ATCL3C 7644,
O157:H7 ZnO NRs UV light - [86]
P. aeruginosa ZnO QDs - - [87]
P. aeruginosa ZnO QDs - - [88]
E. coli ZnO QDs - - [89]
V. cholerae, Mouse intestinal loop ZnO QDs - Coadministeredkanamycin [90]
S. epidermidis, S. aureus,
K. pneumonia, E. coli
ZnO (spheres,
plates, pyramids) - - [91]
MRSA Nano- and micro-sizedZnO coatings -
Coadministered, Gent,
Trim, Rif, Cip, Van [92]
S. aureus, E. coli, mice NHS, ZnO NRs, ZnO NSs - - [93]
a EPEC: Enteropathogenic Escherichia coli; C. jejuni: Campylobacter jejuni; V. cholerae: Vibrio cholerae; MRSA: Methicillin
resistant Staphylococcus aureus; THP-1: Human monocytic cell; M. tuberculosis: Mycobacterium tuberculosis;
A. baumannii: Acinetobacter baumannii; S. aureus: Staphylococcus aureus; S. epidermidis: Staphylococcus epidermidis;
K. pneumonia: Klebsiella pneumonia; MSCL 302: Enterococcus faecalis; ATCL3C 7644: Listeria monocytogenes;
O157:H7: E. coli; P. aeruginosa: Pseudomonas aeruginosa. b ZnO QDs: Zinc oxide quantum dots; Ag QDs: Silver
quantum dots; Cu-ZnO NAs: Cu substituted ZnO nanoassemblies; ZnO-NPYs: ZnO nanopyramids with hexagonal
base; ZnO QDs CVZnO: Crystal violet and zinc oxide nanoparticles; MPA@ZnO-PEP: Silica stabilized ZnO quantum
dots with an antibacterial peptide fragment (UBI29–41) and a near infrared dye MPA (derived from hydrophilic
indocyanine green); NHS: ZnO nanorods−nanoslices hierarchical structure; NRs: Nanorods; NSs: Nanoslices.
c UV: Ultra violet; d Cip: Ciprofloxacin; Cef: Ceftazidime; Met: Methicillin; Van: Vancomycin; Gent: gentamicin;
Trim: trimethoprim; and Rif: rifampicin.
4. Antifungal Capacity of ZnO Nanoplatforms
The antimicrobial power of the ZnO QDs is not limited to bacteria but also to other types
of microorganisms such as fungi. The advantage of these materials is that their effectiveness
can be applied to treat different problems caused by microorganisms such as, infections, diseases,
biocontamination and corrosion.
Growth of fungal pathogens is one of the main problems in agriculture and usually causes
high economic losses to farmers [96]. Different groups have reported the antifungal efficacy of ZnO
QDs against plant pathogens. M. Lin et al. observed that ZnO QDs at concentration higher than
3 mmol/L could markedly reduce the growth of B. cinerea getting even better results against P. expansum
(Figure 10) [97].
The antifungal effect of ZnO QDs has also been proven against other plant pathogens [98–100].
Another important problem related with microorganism and especially with fungi is the biological
colonization of stone heritage what gives rise to its biodegradation. Recently, P. Quintana et al. studied
the antifungal and photocatalytic properties of ZnO, MgO, and Zn/Mg Oxide QDs for the protection
of calcareous stone heritage. Results showed that the growth inhibition of Penicillium oxalicum,
Pestalotiopsis maculans, Paraconiothyrium sp., and Aspergillus niger fungi achieved by Mg1−xZnxO
QDs was higher than that obtained by either of the two pure oxide QDs. The photocatalytic activity
observed was also higher in the case of the mixed oxides compare with the pure ones [101].
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The infection in humans due to the action of opportunistic fungi is also a relevant health problem
nowadays. N.O. Jasim reported the effect of ZnO QDs against two different opportunistic fungi
(A. fumigatus, C. albicans) and observed a significant decreased (p ≥ 0.05) in the radial growth of the
fungus at different concentrations and an increase in the inhibitory effect when increasing the period of
incubation [102]. To increase the antifungal effectiveness against Candida albicans, Ding et al. designed
ZnO QDs coated by chitosan (CS) and functionalized with linoleic acid (LiA). Chitosan has been
reported to present antimicrobial activity because of the presence of positive charges that react with
cellular DNA of some bacteria [103]. Additionally, LiA with Trans-11 and Cis-9 arrangement is one of
the effective acids on fungal growth [104]. The authors studied the effect of CS-LiA QDs compared with
that produced by fluconazole (a potent antifungal drug). Results showed that CS-LiA QDs could inhibit
the growth of fluconazole-resistant clinical strains at similar concentrations to fluconazole, but the
inhibition percent of biofilm formation, for nanoparticles was greater than that of fluconazole [105].
The use of ZnO QDs to synthesize antifungal filters [106] or as antifungal bioglasses [107] for medical
implants or surgical equipment has also been reported as a probe into the versatility of these QDs in
the fight against microorganisms. All ZnO based nanoplatforms for antifungal treatment cited in this
manuscript are summarized in the following Table 3.
Table 3. ZnO nanoplatforms for antifungal treatment.
Type of Fungi Used a Type of Device b Responsive Phenomena c Reference
B. cinerea, P. expansum ZnO QDs - [97]
A. saloni, S. rolfii ZnO QDs - [98]
R. stolonifera, A. flavus, A. nidulans, T. harzianum ZnO QDs - [99]
E. salmonicolor ZnO QDs - [100]
A. niger, P. oxalicum, Paraconiothyrium sp., P. maculans Zn/Mg Oxide QDs UV light [101]
A. fumigatus, C. albicans ZnO QDs - [102]
C. albicans CS-LiA ZnO QDs - [105]
R. stolonifera, P. expansum ZnO QDs - [106]
C. krusei ZnO QDs - [107]
a B. cinerea: Botrytis cinerea; P. expansum: Penicillium expansum; A. saloni: Alternaria saloni; S. rolfii: Sclerotium rolfsii;
A. flavus: Aspergillus flavus; A. nidulans: Aspergillus nidulans; T. harzianum: Trichoderma harzianum; E. salmonicolor:
Erythricium salmonicolor; A. niger: Aspergillus niger; P. oxalicum: Penicillium oxalicum; P. maculans: Pestalotiopsis
maculans; A. fumigatus: Aspergillus fumigatus; C. albicans: Candida albicans; C. krusei: Candida krusei. b ZnO QDs: Zinc
oxide quantum dots; CS-LiA ZnO QDs: ZnO QDs coated by chitosan (CS) and functionalized with linoleic acid
(LiA). c UV: Ultra violet.
5. ZnO Nanoplatforms for Diabetes Treatment
According with the National Diabetes Statistics Report of 2017 [108], 30.3 million people of all ages,
or 9.4% of the U.S. population, had diabetes in 2015 and, unfortunately, the number of people suffering
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from this disease continues to grow over time. These figures make diabetes one of the greatest diseases
facing our society today. In 1934, when it was observed that insulin crystal contained zinc [109],
researchers began to believe that Zn, insulin and diabetes could be intimately related. Nowadays,
it is known that Zn interacts with some elements of insulin signalling pathway and therefore affects
the glucose metabolism. Besides, other aspects of diabetes disease such as β-cell function, glucose
homeostasis, insulin action, and diabetes pathogenesis are also influenced by the presence of this
ion [110]. As the degradation of ZnO results in the release of Zn2+ ions in the media, the number of
studies about the incidence of ZnO QDs in the treatment of diabetes has increased in recent years.
Umrani and Paknikar tested the antidiabetic effect of ZnO QDs in rats and observed that after oral
administration the glucose tolerance was improved. Other factors were also enhanced such us a
reduction in non-esterified fatty acids, triglycerides and glucose in blood and an increase in serum
insulin [111]. In 2015 Asri-Rezaie et al. performed a comparative studied of the antidiabetic activity
and toxic effects of ZnO QDs and zinc sulphate (ZnSO4) in diabetic rats. It was observed that those
treated with ZnO showed greater antidiabetic activity compared to ZnSO4. However, severely elicited
oxidative stress particularly at higher doses was also observed [112]. The efficacy of ZnO QDs in
attenuating pancreatic damage in a rat model of treptozotocin-induced diabetes was also settled one
year later by Kandeel et al. [113]. Other comparative studies including ZnO QDs for antidiabetic studies
have been performed [114]. In 2016, Abu-Risha et al. went a step further and studied the antidiabetic
effect of a co-administered treatment based on ZnO QDs and Vildagliptin, a standard antidiabetic drug.
As a result, the recovery of the function and structure of β cells and a synergistic effect on the therapy
of Type-2 diabetes between this two components was observed [115]. S.N. Kale et al. also explored
the combination effect between ZnO and drugs but in this case the antidiabetic agent was conjugated
to the surface of the QDs. Red Sandalwood (RSW), a potent natural extract anti-diabetic agent was
chosen as model drug. Results showed that ZnO-RSW QDs was more effective against the crude
murine pancreatic glucosidase than any of the two elements (RSW and ZnO QDs) that composed it
administered separately [116]. All ZnO based nanoplatforms for diabetes treatment cited in this are
summarized in Table 4.
Table 4. ZnO nanoplatforms for diabetes treatment.
Model Used Type of Device a Drug/Antibiotic b Reference
Rats ZnO QDs - [111]
Rats ZnO QDs, ZnSO4 - [112]
Rats ZnO QDs - [113]
Rats ZnO, CeO2, Ag QDs, MC - [114]
Rats ZnO QDs Coadministered Vildagliptin [115]
Murine Pancreatic and
Small Intestinal Extracts ZnO QDs Conjugated RSW [116]
a ZnO QDs: Zinc oxide quantum dots; CeO2 QDs: cerium oxide quantum dots; Ag QDs: silver quantum dots;
MC: Momordica charantia. b RSW: Red Sandalwood.
6. ZnO Nanoplatforms with Anti-Inflammatory Properties
The beneficial health effects of both elemental zinc and its salts have been known for a long time,
which is why for several hundred years they have been widely used for therapeutic purposes, including
the anti-inflammatory effectiveness in several common inflammatory dermatoses and for wounds or
ulcers [117]. Since the appearance of nanoparticles, and considering these beneficial properties of zinc
ions, the anti-inflammatory capacity of ZnO QDs have also been studied. H. Alenius et al. investigated
the response produced by topically administration of nano-sized ZnO (nZnO) in the mouse model of
atopic dermatitis (AD) and compared these outcomes to those induced by bulk-sized ZnO (bZnO).
Their experiments clearly demonstrated that nZnO efficiently reduced the thickness of the skin in
the allergic environment compared with the effect produced by bZnO. While topical application of
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bZnO favoured macrophage infiltration, the recruiting of CD8+ and CD4+ T cells in allergic skin was
strongly inhibited by nZnO treatment. These results demonstrated that topical nZnO treatment had
great effects in reducing skin inflammation as consequence of allergen exposition [118].
The anti-inflammatory capacity of ZnO QDs is not limited to skin problems but has also proven to
be very effective for other inflammatory diseases. Shin et al. studied the anti-inflammatory properties of
ZnO in RAW 264.7 murine macrophage cells by measuring their effect in pro-inflammatory mediators.
As can be seen in Figure 11, ZnO QDs clearly reduced inflammation and showed a dose-dependent
effect in the suppression of different protein expressions (COX-2, iNOS, TNF-α and interleukins-1β
and -6) and mRNA [119].
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Inflammat ry bowel diseases are wid spread inflammatory diseases that cau e debilitating health
problems including cancer. In their research, Feng et al. showed that ZnO QDs treatment had markedly
dose-dependent effects on the remission of dextran sulphate sodium influenced ulcerative colitis
in mice. They also demonstrated that the antioxidant and anti-inflammatory abilities of ZnO QDs
were related to their capacity to suppress R S and malondialdehyde production; increase GSH
level; suppress pro-inflammato y cytokines IL-1β and TNF-α and myeloperoxidase (MPO) [120].
Throughout this manuscript the ability of ZnO QDs to produce ROS has been highlighted. However,
the anti-inflammatory properties of these particles are now related to their ability to eliminate them.
Although this may seem contradictory, the truth is that the same properties (large surface area and high
catalytic capacity) that favour the generation of ROS in environments where they are not present is
probably resp sibl f r suppressing them i environments where th y are very abundant. Ulcerative
colitis tissues had 10- to 100-f ld ncreased ROS, and in this case, the antioxidant activity of ZnO
QDs might be the result of electron density transfer from the oxygen to the odd electron placed on
outer orbits of oxygen in O2•− and OH• radicals [121]. Selected ZnO based nanoplatforms with
anti-inflammatory properties are presented in Table 5.
Table 5. ZnO nanoplatforms with anti-inflammatory properties.
Model Used a Type of D vice Referenc
AD model mouse nZnO, bZnO [118]
RAW 264.7 ZnO QDs [119]
mice ZnO QDs [120]
a AD: Atopic dermatitis; RAW 264.7: Murine macrophage cells. b nZnO: nano-sized ZnO; bZnO: bulk-sized ZnO;
ZnO QDs: Zinc oxide quantum dots.
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7. ZnO Nanoplatforms for Wound Healing
The lack of zinc production delaying wound healing is a fact well known in clinic. Already in
1990, the effect of topically applied zinc on leg ulcer healing and its effect on some mechanisms
in wound healing was studied using standardized animal models [122]. After that, several clinical
and experimental studies were performed with elemental Zn and zinc oxide [123]. Results showed
that treatments based in topical ZnO application produced several benefits in re-epithelialization,
wound healing, infections and ulceration among others [124]. Currently, researchers are mostly
focusing their efforts on the design of new materials for wound healing that incorporate the
antibacterial and healing effects of ZnO QDs. R. Jayakumar et al. synthesized a microporous chitosan
hydrogel based on ZnO composite bandages (CZBs) that presented great flexibility. In addition,
ZnO QDs were incorporated into a hydrogel made of chitosan. Results showed that these
nanocomposite bandages presented antibacterial activity and great effects on enhancing blood clotting
and swelling capacity. Infiltration and cell attachment studies were performed showing a clear
penetration and nanocomposite attachment of the cells. Furthermore, as can be seen in Figure 12,
the in vivo test in Sprague-Dawley rats proved the efficacy of these bandages in wound healing as
well as their beneficial effects on collagen deposition and better re-epithelialization [125].
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Manuja et al. synthesized ZnO QDs-loaded-sodium alginate-gum acacia hydrogels (SAGA-ZnO
QDs) by bounding the aldehyde and hydroxyl groups of gluteradehyde and sodium alginate
polymer, respectively. Results showed that hydrogels were biocompatible in peripheral blood
fibroblast/mononuclear cells and could produce inhibition of Pseudomonas aerigunosa and Bacillus cereus.
SAGA-ZnO QDs hydrogels also presented a great healing capacity in sheep fibroblast cells even at low
concentrations [126].
Due to its excellent properties including biocompatibility, haemostatic, bacteriostatic and healing
capacity, chitosan has been extensively used in biomedicine [127]. In 2017, two research groups
reported two different composites based on chitosan and containing ZnO QDs to combine antibacterial
and wound healing properties in the same material. Denkbas et al. proposed the use of scaffolds
containing chitosan/silk sericin (CHT/SS) in combination with lauric acid (LA) or ZnO QDs for
wound dressing applications. Although both combinations CHT/SS/ZnO QDs and CHT/SS/LA had
antimicrobial effect against E. coli and S. aureus, the presence of LA proved to be clearly more efficient
for both bacteria. Besides, these nanocomposites were able to improve the attachment, proliferation and
growth of HaCaT cells, presenting no secondary effects [128]. The second composite was proposed by
Bezerra et al. and consisted in chitosan-based films that contained chondroitin 4-Sulphate, gelatin and
zinc oxide nanoparticles. The wound healing capacity of the system was evaluated in rat models with
full-thickness excision. After six days, results showed a significant decrease (14–35% more) of the
wound compared with that obtained in control ones [129]. Selected ZnO based nanoplatforms for
wound healing are summarized in Table 6.
Table 6. ZnO nanoplatforms for wound healing.
Model Used a Type of Device b Reference
nHDF cells, SD rats CZBs [125]
PBMC, sheep fibroblast cells SAGA-ZnO QDs hydrogels [126]
HaCaT CHT/SS/ZnO QDs, CHT/SS/LA [128]
rats CHT/gel/C4S/ZnO films [129]
a nHDF: Normal human dermal fibroblasts; SD: Sprague-Dawley; PBMC: Peripheral blood mononuclear cells;
HaCaT: Aneuploid immortal keratinocyte cell. b CZBs: Microporous chitosan hydrogel/nano zinc oxide composite
bandages; SAGA-ZnO QDs hydrogels; CHT/SS/ZnO QDs: Chitosan/silk sericin scaffolds combined with ZnO QDs;
CHT/SS/LA: Chitosan/silk sericin scaffolds combined with lauric acid; CHT/gel/C4S/ZnO films: chitosan-based
films containing gelatin, chondroitin 4-Sulphate and ZnO, respectively.
8. Conclusions and Future Outlook
We demonstrate in this article of bibliographic review that zinc oxide nanoparticles present unique
properties: (i) luminescence; (ii) Zn2+ ions release in aqueous media, especially in acidic conditions;
(iii) ROS generation, mainly after being irradiated with UV light; (iv) versatile surface chemistry;
and (v) an easy and economical synthetic process that allows an accurate control of the size and shape
of the particles. All these factors make this nanomaterial a very versatile system, by itself or combined
with other elements. This proves that ZnO nanodevices have applications in virtually all fields of
science, especially in biomedicine. In this review, we report the latest advances derived from their
used in the treatment of cancer and diabetes; their antibacterial, antifungal and anti-inflammatory
efficacy; and their wound healing capacity. Despite all the advances in the understanding of ZnO
nanostructures mechanism of action and biological effects, there is still a lack of knowledge on this
subject, especially on what the long-term effects are. Therefore, a greater knowledge is necessary
to assess whether the already multiple known advantages of the ZnO outweigh the potential risks.
In addition, nowadays, reproducibility in the NPs synthesis process is still a challenge to be achieved.
This, together with the lack of a standardized protocol (concentrations used, times of action, etc.) that
allows comparing the different studies, makes it even more complex to obtain a complete knowledge
of the NPs effects and therefore their clinical translation. However, in view of the facts, the opinion of
the authors is that this is only the beginning and that, in the near future, ZnO based nanodevices will
Nanomaterials 2018, 8, 268 21 of 27
not only will achieve clinical states but other novel theranostic applications will also be proposed for
their use.
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